MSTFA Industries LLC is a Texas technology company developing biomedical instruments, predictive signal-processing systems, and the clinical data infrastructure that connects them.
A spirometry curve captured once a year. An EEG recorded only after the second seizure. A swallow study performed only in hospital. Between these observations, physiology drifts — and the early signal is lost.
We design instruments that move clinical-grade measurement out of the clinic and into continuous use, and we build the data infrastructure that makes those measurements legible to the physician. The portfolio is deliberately narrow: respiratory function, neural monitoring, swallowing analysis, and the FHIR-native data plane underneath them.
Every program is anchored to published literature and reference datasets before a single promotional sentence is written. Validation status is stated plainly: all three devices are pre-clinical.
The three devices standardize on a shared microcontroller platform, shared electrode chemistry, and one signal-processing methodology. Engineering effort compounds instead of fragmenting.
Every record in our infrastructure is exportable through a standard FHIR interface. Retention must be earned through usefulness, not enforced through lock-in.
Each program carries an explicit regulatory posture on the FDA 510(k) pathway, with ISO 13485 quality management planned for manufacture. No ambiguity, no overstatement.
Sets company direction, clinical strategy, and the advisory network. Drives the regulatory and validation roadmap across all programs. Affiliated with the University of Houston.
Owns hardware, firmware, signal processing, and machine learning across the device portfolio, and the Plexus data infrastructure. Responsible for the shared engineering platform underneath every instrument.
Owns finance, unit economics, and capital planning across the portfolio — including the seed round structure and the non-dilutive SBIR track.
Company formation, founding team, literature base, software prototypes, and the shared engineering platform. Complete.
First-party prototype validation across the portfolio; bench comparison against clinical reference instruments. The current raise funds this stage.
IRB-supervised validation studies through academic and clinical partners; structured clinician feedback loops.
FDA 510(k) pre-submission groundwork and filing, program by program, as evidence matures.